Neurocrine Reaffirms Strong Growth Trajectory. Neurocrine Biotech reported robust first quarter results with revenue exceeding $800 million, demonstrating sustained momentum across its portfolio. The company maintained its full-year INGREZZA revenue guidance at $2.7 billion to $2.8 billion, reflecting confidence in continued market expansion for its flagship involuntary movement disorder treatment. INGREZZA remains a cornerstone asset, benefiting from ongoing patient adoption and clinical validation in multiple movement disorder indications. Additionally, Neurocrine highlighted positive momentum for CRENESSITY, its newer treatment option, which is scaling effectively within the market. The company continues executing its strategic acquisition of Soleno Therapeutics, with closure expected during the second quarter.
Post from MarketNews_en
Log in to interact with content.